ATE382337T1 - Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer - Google Patents

Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer

Info

Publication number
ATE382337T1
ATE382337T1 AT06008539T AT06008539T ATE382337T1 AT E382337 T1 ATE382337 T1 AT E382337T1 AT 06008539 T AT06008539 T AT 06008539T AT 06008539 T AT06008539 T AT 06008539T AT E382337 T1 ATE382337 T1 AT E382337T1
Authority
AT
Austria
Prior art keywords
molecular weight
less
release
fraction content
base material
Prior art date
Application number
AT06008539T
Other languages
English (en)
Inventor
Tatsuaki Miyaji
Makoto Sato
Tamaki Murayama
Yohei Hoashi
Hisae Saito
Takao Okada
Yukari Imamura
Yoshimichi Fujiyama
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Application granted granted Critical
Publication of ATE382337T1 publication Critical patent/ATE382337T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06008539T 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer ATE382337T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005131893 2005-04-28

Publications (1)

Publication Number Publication Date
ATE382337T1 true ATE382337T1 (de) 2008-01-15

Family

ID=36952555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06008539T ATE382337T1 (de) 2005-04-28 2006-04-25 Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer

Country Status (4)

Country Link
US (1) US7342048B2 (de)
EP (1) EP1716847B1 (de)
AT (1) ATE382337T1 (de)
DE (1) DE602006000381T2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) * 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
JP6204345B2 (ja) 2011-03-23 2017-09-27 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ 幹細胞の多能性を高めるための組成物及び方法
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US9932560B2 (en) 2011-05-13 2018-04-03 Elixirgen, Llc Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3782628B1 (de) 2013-03-15 2024-08-07 Elixirgen Therapeutics, Inc. Verfahren zur verwendung von zscan4 zur verjüngung menschlicher zellen
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
AU2014340241B2 (en) 2013-10-21 2018-11-01 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
MX2016011517A (es) 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3775236A1 (de) 2018-04-12 2021-02-17 Krystal Biotech, LLC Zusammensetzungen und verfahren zur behandlung von autosomaler rezessiver kongenitaler ichthyose
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
CA3266235A1 (en) 2018-09-26 2025-11-29 Krystal Biotech, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES
WO2020072805A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
EP3921334A1 (de) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Zusammensetzungen und verfahren zur verabreichung von cftr-polypeptiden
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CA3149164A1 (en) 2019-09-03 2021-03-11 Suma Krishnan Compositions and methods for the treatment of congenital ichthyoses
CN110882222B (zh) * 2019-12-05 2021-12-03 北京博恩特药业有限公司 颗粒组合物及制备方法和应用
CA3160199A1 (en) 2019-12-20 2021-06-24 Suma Krishnan Compositions and methods for gene delivery to the airways and/or lungs
CN111658620B (zh) * 2020-04-30 2022-04-19 天津医科大学口腔医院 一种透明质酸-帕瑞昔布plga微球及其制备方法和应用
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
AU2024229184A1 (en) 2023-03-02 2025-08-28 Krystal Biotech, Inc. Interleukin-2 and interleukin-12 for cancer therapy
WO2024214081A1 (en) 2023-04-13 2024-10-17 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328204A (en) * 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60181029A (ja) 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
JP3168263B2 (ja) 1984-07-06 2001-05-21 和光純薬工業株式会社 新規重合体及びこれを用いた医薬
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
JP3254449B2 (ja) 1990-04-13 2002-02-04 武田薬品工業株式会社 生体内分解型高分子重合物
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5614390A (en) 1996-06-14 1997-03-25 Becton, Dickinson And Company Species-specific detection of Mycobacterium kansasii
PT839525E (pt) * 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
TR200002059T2 (tr) 1998-01-16 2001-01-22 Takeda Chemical Industries, Ltd. Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
JP2004155792A (ja) 2001-06-29 2004-06-03 Takeda Chem Ind Ltd 徐放性組成物およびその製造法
JP3902518B2 (ja) 2001-06-29 2007-04-11 武田薬品工業株式会社 徐放性組成物用乳酸−グリコール酸重合体の製造法
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
JP5188670B2 (ja) 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法

Also Published As

Publication number Publication date
DE602006000381D1 (de) 2008-02-14
US20060246139A1 (en) 2006-11-02
EP1716847A1 (de) 2006-11-02
DE602006000381T2 (de) 2008-12-18
US7342048B2 (en) 2008-03-11
EP1716847B1 (de) 2008-01-02

Similar Documents

Publication Publication Date Title
ATE382337T1 (de) Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
CY1115707T1 (el) Στερεα σταθεροποιημενα θεραπευτικα συστηματα ταχειας και/ή τροποποιημενης απελευθερωσης για τη χορηγηση απο του στοματος υγρων δραστικων ουσιων, εκδοχων ή τροφιμων
WO2009132265A3 (en) Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
NO20071853L (no) Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.
EP1786400A4 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
NZ601200A (en) Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
BR0002880A (pt) Composição farmacêutica de liberação controlada termoformável sólida
WO2010138544A3 (en) Oral care formulations that enhance amount of soluble zinc
MX2010002780A (es) Formulacion de farmaco resistente al abuso.
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
PE20050728A1 (es) Forma de dosificacion a prueba de abuso
CO5540367A2 (es) Composicion de liberacion controlada y metodo para producirla
WO2006099514A3 (en) Drug delivery compositions and related methods
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles
ATE471711T1 (de) Subkutane implantate, die über einen längeren zeitraum einen wirkstoff freisetzen
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
BRPI0620185B8 (pt) formulação farmacêutica, comprimidos, e, processo para a preparação de uma formulação farmacêutica
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1716847

Country of ref document: EP